Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how blood tests can help doctors predict if autoimmune diseases might come back in patients treated with a medicine called rituximab. Rituximab works by targeting certain immune cells called B-cells, which play a role in autoimmune conditions like lupus, rheumatoid arthritis, and some blood disorders. The study will look at specific types of B-cells and the levels of rituximab and antibodies against it in the blood to see if these measures can signal when a disease flare-up might happen.

People who may join the study are adults being treated with rituximab for autoimmune conditions such as primary immune thrombocytopenia (a low platelet count), autoimmune hemolytic anemia (where the body attacks red blood cells), lupus, rheumatoid arthritis, and certain types of vasculitis (inflammation of blood vessels). Participants will continue with their usual medical care, including routine blood tests every few months during the first year of treatment. The study will use leftover blood from these tests to measure additional factors without extra blood draws. This helps researchers understand better who might be at risk for disease relapse and could lead to improved monitoring and treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patient who undergo rituximab treatment according to routine care and having one of the following disorder:
• • primary immune thrombocytopenia
• • primary autoimmune hemolytic anemia
• • systmic lupus erythematous
• • systemic sclerosis
• • rheumatoid arthritis
• • inflammatory myopathy
• • ANCA associated vasculitis
• • Cryoglobulinemic vasculitis
• Exclusion Criteria:
• • Patients undergoing multiple immunosuppressive drugs because of refractory disease or concomitant hemopathy or malignancy